On February 4, Novo Nordisk published its ninth integrated annual report detailing the company’s social, environmental and financial results for 2012.
The 2012 report describes how Novo Nordisk’s Triple Bottom Line business principle continues to support the company’s long-term value creation.
“We publish an integrated report because we think it’s important that when we talk about sustainability, we also hold ourselves accountable to our stakeholders,” says Lise Kingo, Executive Vice President, Corporate Relations, Novo Nordisk.
In the 2012 report, Novo Nordisk introduces the company’s updated global access to diabetes care strategy to close the gap between health needs and healthcare supply and states its goal of reaching an estimated 40 million patients with medical care by 2020.
Novo Nordisk’s 2012 social and environmental performance includes:
- reaching an estimated 23 million people with injectable diabetes care products during 2012, up from 21 million in 2011
- educating or training 1,274,000 healthcare providers to improve diabetes care, up from 835,000 in 2011
- increasing the diversity of senior management teams to 66%, up from 62% in 2011
- an increase in CO2 emissions from energy consumption of 30% compared to 2011, with an absolute reduction of 44% compared to 2004
- an increase in water consumption of 16% compared to 2011
- an increase in energy consumption of 11% compared to 2011
The company’s increase in energy and water consumption is directly linked to the increased production volume output. The increase in CO2 emissions from energy consumption is driven by the phase-in of a new filling plant in Tianjin, China, and a larger production volume at the main production site in Kalundborg, Denmark.
In the absence of global standards for inclusive reporting, the report was prepared in respect of international standards for mandatory and voluntary reporting:
- International Financial Reporting Standards (IFRS)
- The accountability standard, the AA1000 (2008) Framework, which includes AA1000APS (2008) and AA1000AS (2008)
- Global Reporting Initiative (GRI) G3 Sustainability Reporting Guidelines
- UN Global Compact LEAD, Communication on Progress
- US Sarbanes-Oxley Act requirements for financial reporting
- International Standards on Assurance Engagements (ISAE) 3000
- Danish Corporate Governance Recommendations
Source: Novo Nordisk.
About Novo Nordisk
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 34,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit www.novonordisk.com.